Earnings call transcript: MustGrow Biologics posts Q2 2026 profit as sales grow

MustGrow Biologics reported a Q2 2026 net profit of CAD 300,000 versus a CAD 1.1M loss a year earlier, driven largely by CAD 1.4M licensing revenue while TerraSante product sales were only CAD 75,000 and gross profit was negative (loss of CAD 17,000). Margin pressure is attributed to manufacturing disruptions and high Asia-to-U.S. air freight costs; management expects gross margins to recover toward 25%-30% as shipments shift to cheaper ocean freight and production stabilizes. Shares were down 0.73% to $680, suggesting investors viewed progress on profitability as real but still cautious given ongoing supply/margin constraints.

Analysis

The market should treat this as a quality-of-earnings issue, not a clean turnaround. The reported profit is being underwritten by non-core licensing income and lower overhead; the operating product still appears margin-negative once logistics are normalized, which means the real P&L inflection depends on execution, not demand. In the near term, the biggest sensitivity is whether inventory can be shipped via ocean freight without losing the selling season; if that slips, the 2027 positive cash-flow target becomes a financing story again.

Second-order, Bayer’s economic exposure is more option value than current earnings impact: the first milestone validates the platform, but the real payoff is years away and contingent on regulatory and technical de-risking. The clearer tradable beneficiary, if demand proves durable, is Nutrien/NTR as the distribution layer that can capture recurring crop-input wallet share without taking much balance-sheet risk. By contrast, peers in synthetic inputs and broader biostimulants are not facing an immediate industry-wide demand shock; this is still a niche product story.

Contrarian view: consensus may be overfocusing on the headline profitability swing and underweighting that core gross margin remains fragile and cash is still modest relative to ongoing operating needs. The key falsifier over the next 1-3 months is a Q4/Q1 shipment ramp that does not show up in revenue or margin recovery; if gross margin does not revert toward the mid-20s, the thesis is that demand is real but monetization is not. For BAYRY, the event is too small to matter financially this year; it is a long-dated free option, not a catalyst for multiple expansion.

Key Decisions for Investors

• MGROF: do not chase the stock on the quarter; only consider a tactical long after Q4/Q1 data confirms ocean-freight transition and gross margin recovery toward 20%+ for at least one quarter.
• MGROF: set a hard alert if cash falls below CAD 3.0m or if the next update shows continued negative gross profit despite higher sales; that would re-open dilution risk and invalidate the turnaround narrative.
• BAYRY / MGROF pair: small long BAYRY vs short MGROF over 1-3 months as a quality-vs-execution expression; Bayer has low-cost optionality, while MustGrow still needs flawless operations to re-rate.
• NTR: keep on watch for channel checks with Nutrien distribution; if repeat-order momentum broadens beyond strawberries/potatoes, NTR could capture incremental share in specialty ag inputs with limited downside.